Bristol-Myers Squibb Company
IMMUNOTHERAPEUTIC DOSING REGIMENS COMPRISING POMALIDOMIDE AND AN ANTI-CS1 ANTIBODY FOR TREATING CANCER
Last updated:
Abstract:
The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with one or more immunotherapeutic agents.
Status:
Application
Type:
Utility
Filling date:
15 Jan 2021
Issue date:
27 May 2021